Capricor Therapeutics Inc CAPR.OQ CAPR.O is expected to show a fall in quarterly revenue when it reports results on March 12 for the period ending December 31 2025
(Majority is on total revenue basis including milstone and other revenue)
LSEG's mean analyst estimate for Capricor Therapeutics Inc is for a loss of 54 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Capricor Therapeutics Inc is $50.00, about 63.2% above its last closing price of $30.63
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.56 | -0.55 | -0.54 | Beat | 1.4 |
Jun. 30 2025 | -0.48 | -0.47 | -0.57 | Missed | -21.6 |
Mar. 31 2025 | -0.31 | -0.32 | -0.53 | Missed | -67.4 |
Dec. 31 2024 | -0.32 | -0.26 | -0.16 | Beat | 39.2 |
Sep. 30 2024 | -0.35 | -0.36 | -0.38 | Missed | -6 |
Jun. 30 2024 | -0.35 | -0.36 | -0.35 | Beat | 1.7 |
Mar. 31 2024 | -0.11 | -0.11 | -0.31 | Missed | -173.5 |
Dec. 31 2023 | -0.10 | -0.09 | -0.02 | Beat | 77.8 |
This summary was machine generated March 10 at 20:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments